KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Charles River Laboratories International (CRL) Current Deferred Revenue (2016 - 2025)

Charles River Laboratories International (CRL) has 17 years of Current Deferred Revenue data on record, last reported at $210.4 million in Q4 2025.

  • For Q4 2025, Current Deferred Revenue fell 25.65% year-over-year to $210.4 million; the TTM value through Dec 2025 reached $210.4 million, down 25.65%, while the annual FY2025 figure was $210.4 million, 25.65% down from the prior year.
  • Current Deferred Revenue reached $210.4 million in Q4 2025 per CRL's latest filing, down from $237.7 million in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $290.0 million in Q4 2022 and bottomed at $210.4 million in Q4 2025.
  • Average Current Deferred Revenue over 5 years is $247.8 million, with a median of $250.5 million recorded in 2025.
  • Peak YoY movement for Current Deferred Revenue: soared 32.0% in 2022, then fell 25.65% in 2025.
  • A 5-year view of Current Deferred Revenue shows it stood at $219.7 million in 2021, then surged by 32.0% to $290.0 million in 2022, then fell by 5.86% to $273.0 million in 2023, then grew by 3.66% to $283.0 million in 2024, then dropped by 25.65% to $210.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Current Deferred Revenue were $210.4 million in Q4 2025, $237.7 million in Q3 2025, and $268.3 million in Q2 2025.